In situ complexation of sgRNA and Cas12a improves the performance of a one-pot RPA–CRISPR-Cas12 assay

Daniel A. Richards,Jake M. Lesinski,Thomas Moragues,Prerit Mathur,Yang Shen,Carolina Paganini,Léonard Bezinge,Bo Verberckmoes,Bodine Van Eenooghe,Stavros Stavrakis,Andrew J. deMello

DOI: https://doi.org/10.26434/chemrxiv-2024-82q4c

2024-04-04

Abstract:Due to their ability to selectively target pathogen-specific nucleic acids, CRISPR-Cas systems are increasingly being employed as diagnostic tools. “One pot” assays that combine nucleic acid amplification and CRISPR-Cas systems (NAAT–CRISPR-Cas) in a single step have emerged as one of the most popular CRISPR-Cas biosensing formats. However, operational simplicity comes at a cost, with one-pot assays typically being less sensitive than corresponding two-step NAAT–CRISPR-Cas assays and often failing to detect targets at low concentrations. It is thought that these performance reductions result from the competition between the two enzymatic processes driving the assay, namely Cas-mediated cis-cleavage and polymerase-mediated amplification of the target DNA. Herein, we describe a novel one-pot RPA–Cas12a assay that circumvents this issue by leveraging in situ complexation of the target-specific sgRNA and Cas12a to purposefully limit the concentration of active Cas12a during the early stages of the assay. Using a clinically relevant assay against a DNA target for HPV-16, we show how this in situ format reduces competition between target cleavage and amplification and engenders significant improvements in detection limit when compared to the traditional one-pot assay format, even in patient-derived samples. Finally, to gain further insight into the assay, we use experimental data to formulate a mechanistic model describing the competition between the Cas enzyme and nucleic acid amplification. These findings suggest that purposefully limiting cis-cleavage rates of Cas proteins is a viable strategy for improving the performance of one-pot NAAT–CRISPR-Cas assays.

Chemistry

What problem does this paper attempt to address?

This article mainly discusses how to improve a one-step nucleic acid amplification and CRISPR-Cas system detection method called RPA-CRISPR-Cas12 to enhance its sensitivity in detecting low-concentration target DNA. In the study, the authors proposed to reduce competition and improve the detection limit by limiting the concentration of early-stage active Cas12a through in-situ complexation of sgRNA and Cas12a. They demonstrated the significant improvement in detection limit, especially in the case of low-concentration target molecules, through experiments on clinically relevant samples such as HPV-16 DNA. Additionally, they constructed a kinetic model based on experimental data to describe the competition between Cas enzyme and nucleic acid amplification. The paper concludes that selectively limiting the cis-cleavage rate of Cas protein is an effective strategy to enhance the performance of one-step NAAT-CRISPR-Cas detection.